Changes in lipoprotein lipase and endothelial lipase mass in familial hypercholesterolemia during three-drug lipid-lowering combination therapy View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-04-02

AUTHORS

Hayato Tada, Junji Kobayashi, Masa-aki Kawashiri, Kazuya Miyashita, Atsushi Nohara, Akihiro Inazu, Katsuyuki Nakajima, Hiroshi Mabuchi, Masakazu Yamagishi

ABSTRACT

BackgroundThis study was performed to compare the effects of three different lipid-lowering therapies (statins, ezetimibe, and colestimide) on lipoprotein lipase and endothelial lipase masses in pre-heparin plasma (pre-heparin LPL and EL mass, respectively) from patients with familial hypercholesterolemia (FH). FH is usually treated by coadministration of these three drugs.MethodsThe pre-heparin LPL and EL masses were measured in fresh frozen plasma drawn and stored at various time points during coadministration of the three drugs from patients with heterozygous FH harboring a single mutation in the LDL receptor (n = 16, mean age 63 years). The patients were randomly divided into two groups based on the timing when ezetimibe was added.ResultsPlasma LPL mass concentration was significantly reduced by rosuvastatin at 20 mg/day (median = 87.4 [IQR: 71.4–124.7] to 67.5 [IQR: 62.1–114.3] ng/ml, P < 0.05). In contrast, ezetimibe at 10 mg/day as well as colestimide at 3.62 g/day did not alter its level substantially (median = 67.5 [IQR: 62.1–114.3] to 70.2 [IQR: 58.3–106.2], and to 74.9 [IQR: 55.6–101.3] ng/ml, respectively) in the group starting with rosuvastatin followed by the addition of ezetimibe and colestimide. On the other hand, the magnitude in LPL mass reduction was lower in the group starting with ezetimibe at 10 mg/day before reaching the maximum dose of 20 mg/day of rosuvastatin. Plasma EL mass concentration was significantly increased by rosuvastatin at 20 mg/day (median = 278.8 [IQR: 186.7–288.7] to 297.0 [IQR: 266.2–300.2] ng/ml, P < 0.05), whereas other drugs did not significantly alter its level.ConclusionThe effects on changes of LPL and EL mass differed depending on the lipid-lowering therapy, which may impact the prevention of atherosclerosis differently. More... »

PAGES

66

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12944-016-0238-z

DOI

http://dx.doi.org/10.1186/s12944-016-0238-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1015287482

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27039080


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anticholesteremic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Epichlorohydrin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ezetimibe", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hyperlipoproteinemia Type II", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Imidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lipase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lipoprotein Lipase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, LDL", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Resins, Synthetic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rosuvastatin Calcium", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, 920-8641, Kanazawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.9707.9", 
          "name": [
            "Division of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, 920-8641, Kanazawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tada", 
        "givenName": "Hayato", 
        "id": "sg:person.01216703022.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216703022.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of General Medicine, Kanazawa Medical University, Uchinada, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411998.c", 
          "name": [
            "Department of General Medicine, Kanazawa Medical University, Uchinada, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kobayashi", 
        "givenName": "Junji", 
        "id": "sg:person.013222157034.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013222157034.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, 920-8641, Kanazawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.9707.9", 
          "name": [
            "Division of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, 920-8641, Kanazawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kawashiri", 
        "givenName": "Masa-aki", 
        "id": "sg:person.0770006522.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770006522.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Immuno-Biological Laboratories Co., Ltd, Fujioka, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Immuno-Biological Laboratories Co., Ltd, Fujioka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miyashita", 
        "givenName": "Kazuya", 
        "id": "sg:person.01214230312.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214230312.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Advanced Research in Community Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.9707.9", 
          "name": [
            "Department of Advanced Research in Community Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nohara", 
        "givenName": "Atsushi", 
        "id": "sg:person.01337767061.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337767061.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Laboratory Science, Molecular Biochemistry and Molecular Biology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.9707.9", 
          "name": [
            "Department of Laboratory Science, Molecular Biochemistry and Molecular Biology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Inazu", 
        "givenName": "Akihiro", 
        "id": "sg:person.0603455520.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603455520.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.256642.1", 
          "name": [
            "Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakajima", 
        "givenName": "Katsuyuki", 
        "id": "sg:person.07671121012.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07671121012.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Advanced Research in Community Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.9707.9", 
          "name": [
            "Department of Advanced Research in Community Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mabuchi", 
        "givenName": "Hiroshi", 
        "id": "sg:person.01154062341.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154062341.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, 920-8641, Kanazawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.9707.9", 
          "name": [
            "Division of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, 920-8641, Kanazawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamagishi", 
        "givenName": "Masakazu", 
        "id": "sg:person.01111610241.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111610241.58"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/ng.2795", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043368998", 
          "https://doi.org/10.1038/ng.2795"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng.2480", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024601187", 
          "https://doi.org/10.1038/ng.2480"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/8904_2014_404", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040856556", 
          "https://doi.org/10.1007/8904_2014_404"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature13917", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025090131", 
          "https://doi.org/10.1038/nature13917"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-04-02", 
    "datePublishedReg": "2016-04-02", 
    "description": "BackgroundThis study was performed to compare the effects of three different lipid-lowering therapies (statins, ezetimibe, and colestimide) on lipoprotein lipase and endothelial lipase masses in pre-heparin plasma (pre-heparin LPL and EL mass, respectively) from patients with familial hypercholesterolemia (FH). FH is usually treated by coadministration of these three drugs.MethodsThe pre-heparin LPL and EL masses were measured in fresh frozen plasma drawn and stored at various time points during coadministration of the three drugs from patients with heterozygous FH harboring a single mutation in the LDL receptor (n\u2009=\u200916, mean age 63\u00a0years). The patients were randomly divided into two groups based on the timing when ezetimibe was added.ResultsPlasma LPL mass concentration was significantly reduced by rosuvastatin at 20\u00a0mg/day (median\u2009=\u200987.4 [IQR: 71.4\u2013124.7] to 67.5 [IQR: 62.1\u2013114.3] ng/ml, P\u2009<\u20090.05). In contrast, ezetimibe at 10\u00a0mg/day as well as colestimide at 3.62\u00a0g/day did not alter its level substantially (median\u2009=\u200967.5 [IQR: 62.1\u2013114.3] to 70.2 [IQR: 58.3\u2013106.2], and to 74.9 [IQR: 55.6\u2013101.3] ng/ml, respectively) in the group starting with rosuvastatin followed by the addition of ezetimibe and colestimide. On the other hand, the magnitude in LPL mass reduction was lower in the group starting with ezetimibe at 10\u00a0mg/day before reaching the maximum dose of 20\u00a0mg/day of rosuvastatin. Plasma EL mass concentration was significantly increased by rosuvastatin at 20\u00a0mg/day (median\u2009=\u2009278.8 [IQR: 186.7\u2013288.7] to 297.0 [IQR: 266.2\u2013300.2] ng/ml, P\u2009<\u20090.05), whereas other drugs did not significantly alter its level.ConclusionThe effects on changes of LPL and EL mass differed depending on the lipid-lowering therapy, which may impact the prevention of atherosclerosis differently.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12944-016-0238-z", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.6155102", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.5867805", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.5869116", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1031029", 
        "issn": [
          "1476-511X"
        ], 
        "name": "Lipids in Health and Disease", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "keywords": [
      "lipid-lowering therapy", 
      "familial hypercholesterolemia", 
      "lipoprotein lipase", 
      "addition of ezetimibe", 
      "prevention of atherosclerosis", 
      "heterozygous familial hypercholesterolemia", 
      "different lipid-lowering therapies", 
      "fresh frozen plasma", 
      "pre-heparin plasma", 
      "lipid-lowering combination therapy", 
      "combination therapy", 
      "frozen plasma", 
      "BackgroundThis study", 
      "LDL receptor", 
      "maximum dose", 
      "rosuvastatin", 
      "patients", 
      "EL mass", 
      "therapy", 
      "ezetimibe", 
      "time points", 
      "coadministration", 
      "drugs", 
      "hypercholesterolemia", 
      "days", 
      "LPL", 
      "group", 
      "colestimide", 
      "atherosclerosis", 
      "mass reduction", 
      "dose", 
      "receptors", 
      "prevention", 
      "single mutation", 
      "levels", 
      "plasma", 
      "lipase", 
      "mass", 
      "effect", 
      "changes", 
      "concentration", 
      "mutations", 
      "study", 
      "contrast", 
      "timing", 
      "reduction", 
      "addition", 
      "hand", 
      "point", 
      "mass concentration", 
      "magnitude"
    ], 
    "name": "Changes in lipoprotein lipase and endothelial lipase mass in familial hypercholesterolemia during three-drug lipid-lowering combination therapy", 
    "pagination": "66", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1015287482"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12944-016-0238-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27039080"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12944-016-0238-z", 
      "https://app.dimensions.ai/details/publication/pub.1015287482"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_713.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12944-016-0238-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12944-016-0238-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12944-016-0238-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12944-016-0238-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12944-016-0238-z'


 

This table displays all metadata directly associated to this object as RDF triples.

270 TRIPLES      21 PREDICATES      97 URIs      85 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12944-016-0238-z schema:about N09fc1f434487461c89a58dc138dfce81
2 N0f35bbe45e14416499b44cf56830e893
3 N24457bb097c64133b48d85c0da1152ed
4 N328ddd3f692c4a1693d0abe13e097993
5 N4625c5838e2c4b228e44dd8bedeb7a29
6 N504d855a9758469188ad1c0173395538
7 N6497e4dfdc7141c5be46c88a0ad21a7a
8 N680721da8773471fada19923bbc04f0b
9 N68e6a648a660427b827760aaefc16869
10 N6e12a7d64da649399a7b82a450945d63
11 N6f61909662e24b88adaa148030c5ac6b
12 N80d5809c5356456f82a6062d08cb3fdb
13 N969c816660c94353be5f3fd8730a3262
14 Nab9572ccae464bbe8b297847b38e7402
15 Nc10f829b17004c0584f41168de4479d9
16 Ncbfded259775408a99b96b3d846f1478
17 Ne648b00851e94aec9e728321d7c80238
18 anzsrc-for:11
19 anzsrc-for:1103
20 schema:author N7f8a1a26d9c241b7b1651f82eb4db594
21 schema:citation sg:pub.10.1007/8904_2014_404
22 sg:pub.10.1038/nature13917
23 sg:pub.10.1038/ng.2480
24 sg:pub.10.1038/ng.2795
25 schema:datePublished 2016-04-02
26 schema:datePublishedReg 2016-04-02
27 schema:description BackgroundThis study was performed to compare the effects of three different lipid-lowering therapies (statins, ezetimibe, and colestimide) on lipoprotein lipase and endothelial lipase masses in pre-heparin plasma (pre-heparin LPL and EL mass, respectively) from patients with familial hypercholesterolemia (FH). FH is usually treated by coadministration of these three drugs.MethodsThe pre-heparin LPL and EL masses were measured in fresh frozen plasma drawn and stored at various time points during coadministration of the three drugs from patients with heterozygous FH harboring a single mutation in the LDL receptor (n = 16, mean age 63 years). The patients were randomly divided into two groups based on the timing when ezetimibe was added.ResultsPlasma LPL mass concentration was significantly reduced by rosuvastatin at 20 mg/day (median = 87.4 [IQR: 71.4–124.7] to 67.5 [IQR: 62.1–114.3] ng/ml, P < 0.05). In contrast, ezetimibe at 10 mg/day as well as colestimide at 3.62 g/day did not alter its level substantially (median = 67.5 [IQR: 62.1–114.3] to 70.2 [IQR: 58.3–106.2], and to 74.9 [IQR: 55.6–101.3] ng/ml, respectively) in the group starting with rosuvastatin followed by the addition of ezetimibe and colestimide. On the other hand, the magnitude in LPL mass reduction was lower in the group starting with ezetimibe at 10 mg/day before reaching the maximum dose of 20 mg/day of rosuvastatin. Plasma EL mass concentration was significantly increased by rosuvastatin at 20 mg/day (median = 278.8 [IQR: 186.7–288.7] to 297.0 [IQR: 266.2–300.2] ng/ml, P < 0.05), whereas other drugs did not significantly alter its level.ConclusionThe effects on changes of LPL and EL mass differed depending on the lipid-lowering therapy, which may impact the prevention of atherosclerosis differently.
28 schema:genre article
29 schema:isAccessibleForFree true
30 schema:isPartOf N39dbf037f7784cdaaf6634bd57e31b85
31 N68d213d5313b4729903486b3c6e05bd1
32 sg:journal.1031029
33 schema:keywords BackgroundThis study
34 EL mass
35 LDL receptor
36 LPL
37 addition
38 addition of ezetimibe
39 atherosclerosis
40 changes
41 coadministration
42 colestimide
43 combination therapy
44 concentration
45 contrast
46 days
47 different lipid-lowering therapies
48 dose
49 drugs
50 effect
51 ezetimibe
52 familial hypercholesterolemia
53 fresh frozen plasma
54 frozen plasma
55 group
56 hand
57 heterozygous familial hypercholesterolemia
58 hypercholesterolemia
59 levels
60 lipase
61 lipid-lowering combination therapy
62 lipid-lowering therapy
63 lipoprotein lipase
64 magnitude
65 mass
66 mass concentration
67 mass reduction
68 maximum dose
69 mutations
70 patients
71 plasma
72 point
73 pre-heparin plasma
74 prevention
75 prevention of atherosclerosis
76 receptors
77 reduction
78 rosuvastatin
79 single mutation
80 study
81 therapy
82 time points
83 timing
84 schema:name Changes in lipoprotein lipase and endothelial lipase mass in familial hypercholesterolemia during three-drug lipid-lowering combination therapy
85 schema:pagination 66
86 schema:productId N3d4c4274cdd04f418bd18b0417f68469
87 Nac47dd3152764797a00a8dd001dd834f
88 Nfae1bfcef6b847bcb1a6e4b10257028d
89 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015287482
90 https://doi.org/10.1186/s12944-016-0238-z
91 schema:sdDatePublished 2022-09-02T16:00
92 schema:sdLicense https://scigraph.springernature.com/explorer/license/
93 schema:sdPublisher Nbdc5140bdf85422ab335f15bcbff7866
94 schema:url https://doi.org/10.1186/s12944-016-0238-z
95 sgo:license sg:explorer/license/
96 sgo:sdDataset articles
97 rdf:type schema:ScholarlyArticle
98 N09fc1f434487461c89a58dc138dfce81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Hyperlipoproteinemia Type II
100 rdf:type schema:DefinedTerm
101 N0f35bbe45e14416499b44cf56830e893 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Anticholesteremic Agents
103 rdf:type schema:DefinedTerm
104 N24457bb097c64133b48d85c0da1152ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Receptors, LDL
106 rdf:type schema:DefinedTerm
107 N328ddd3f692c4a1693d0abe13e097993 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Drug Therapy, Combination
109 rdf:type schema:DefinedTerm
110 N39dbf037f7784cdaaf6634bd57e31b85 schema:issueNumber 1
111 rdf:type schema:PublicationIssue
112 N3d4c4274cdd04f418bd18b0417f68469 schema:name doi
113 schema:value 10.1186/s12944-016-0238-z
114 rdf:type schema:PropertyValue
115 N4625c5838e2c4b228e44dd8bedeb7a29 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Middle Aged
117 rdf:type schema:DefinedTerm
118 N4c3c8bc27c784aaf956df4f2348f3112 rdf:first sg:person.07671121012.35
119 rdf:rest Neefe92f5979d4fefb8e3e975ea16eb63
120 N504d855a9758469188ad1c0173395538 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Ezetimibe
122 rdf:type schema:DefinedTerm
123 N54f257fa16174498a0093de2bf1bb5e1 rdf:first sg:person.01337767061.47
124 rdf:rest N83f3f4bcb9e04a69aa1ab75445dfe32a
125 N6497e4dfdc7141c5be46c88a0ad21a7a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Epichlorohydrin
127 rdf:type schema:DefinedTerm
128 N680721da8773471fada19923bbc04f0b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Female
130 rdf:type schema:DefinedTerm
131 N68d213d5313b4729903486b3c6e05bd1 schema:volumeNumber 15
132 rdf:type schema:PublicationVolume
133 N68e6a648a660427b827760aaefc16869 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Resins, Synthetic
135 rdf:type schema:DefinedTerm
136 N6e12a7d64da649399a7b82a450945d63 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Lipoprotein Lipase
138 rdf:type schema:DefinedTerm
139 N6e1f749fe0df4d93ac0b8e8e062295d5 rdf:first sg:person.0770006522.11
140 rdf:rest Nbe95cedf3cfd43b28b9f9865d101473b
141 N6f61909662e24b88adaa148030c5ac6b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Aged
143 rdf:type schema:DefinedTerm
144 N7f8a1a26d9c241b7b1651f82eb4db594 rdf:first sg:person.01216703022.43
145 rdf:rest Ncd4c4b75e35c4b40855e4d50184a16ac
146 N80d5809c5356456f82a6062d08cb3fdb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Imidazoles
148 rdf:type schema:DefinedTerm
149 N83f3f4bcb9e04a69aa1ab75445dfe32a rdf:first sg:person.0603455520.27
150 rdf:rest N4c3c8bc27c784aaf956df4f2348f3112
151 N969c816660c94353be5f3fd8730a3262 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Rosuvastatin Calcium
153 rdf:type schema:DefinedTerm
154 Nab9572ccae464bbe8b297847b38e7402 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Adult
156 rdf:type schema:DefinedTerm
157 Nac47dd3152764797a00a8dd001dd834f schema:name dimensions_id
158 schema:value pub.1015287482
159 rdf:type schema:PropertyValue
160 Nbdc5140bdf85422ab335f15bcbff7866 schema:name Springer Nature - SN SciGraph project
161 rdf:type schema:Organization
162 Nbe95cedf3cfd43b28b9f9865d101473b rdf:first sg:person.01214230312.82
163 rdf:rest N54f257fa16174498a0093de2bf1bb5e1
164 Nc10f829b17004c0584f41168de4479d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Lipase
166 rdf:type schema:DefinedTerm
167 Nc31227995bb743e7bf9e28267fe4cd53 rdf:first sg:person.01111610241.58
168 rdf:rest rdf:nil
169 Ncbfded259775408a99b96b3d846f1478 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Male
171 rdf:type schema:DefinedTerm
172 Ncd4c4b75e35c4b40855e4d50184a16ac rdf:first sg:person.013222157034.80
173 rdf:rest N6e1f749fe0df4d93ac0b8e8e062295d5
174 Ne648b00851e94aec9e728321d7c80238 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Humans
176 rdf:type schema:DefinedTerm
177 Neefe92f5979d4fefb8e3e975ea16eb63 rdf:first sg:person.01154062341.76
178 rdf:rest Nc31227995bb743e7bf9e28267fe4cd53
179 Nfae1bfcef6b847bcb1a6e4b10257028d schema:name pubmed_id
180 schema:value 27039080
181 rdf:type schema:PropertyValue
182 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
183 schema:name Medical and Health Sciences
184 rdf:type schema:DefinedTerm
185 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
186 schema:name Clinical Sciences
187 rdf:type schema:DefinedTerm
188 sg:grant.5867805 http://pending.schema.org/fundedItem sg:pub.10.1186/s12944-016-0238-z
189 rdf:type schema:MonetaryGrant
190 sg:grant.5869116 http://pending.schema.org/fundedItem sg:pub.10.1186/s12944-016-0238-z
191 rdf:type schema:MonetaryGrant
192 sg:grant.6155102 http://pending.schema.org/fundedItem sg:pub.10.1186/s12944-016-0238-z
193 rdf:type schema:MonetaryGrant
194 sg:journal.1031029 schema:issn 1476-511X
195 schema:name Lipids in Health and Disease
196 schema:publisher Springer Nature
197 rdf:type schema:Periodical
198 sg:person.01111610241.58 schema:affiliation grid-institutes:grid.9707.9
199 schema:familyName Yamagishi
200 schema:givenName Masakazu
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111610241.58
202 rdf:type schema:Person
203 sg:person.01154062341.76 schema:affiliation grid-institutes:grid.9707.9
204 schema:familyName Mabuchi
205 schema:givenName Hiroshi
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154062341.76
207 rdf:type schema:Person
208 sg:person.01214230312.82 schema:affiliation grid-institutes:None
209 schema:familyName Miyashita
210 schema:givenName Kazuya
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214230312.82
212 rdf:type schema:Person
213 sg:person.01216703022.43 schema:affiliation grid-institutes:grid.9707.9
214 schema:familyName Tada
215 schema:givenName Hayato
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216703022.43
217 rdf:type schema:Person
218 sg:person.013222157034.80 schema:affiliation grid-institutes:grid.411998.c
219 schema:familyName Kobayashi
220 schema:givenName Junji
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013222157034.80
222 rdf:type schema:Person
223 sg:person.01337767061.47 schema:affiliation grid-institutes:grid.9707.9
224 schema:familyName Nohara
225 schema:givenName Atsushi
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337767061.47
227 rdf:type schema:Person
228 sg:person.0603455520.27 schema:affiliation grid-institutes:grid.9707.9
229 schema:familyName Inazu
230 schema:givenName Akihiro
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603455520.27
232 rdf:type schema:Person
233 sg:person.07671121012.35 schema:affiliation grid-institutes:grid.256642.1
234 schema:familyName Nakajima
235 schema:givenName Katsuyuki
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07671121012.35
237 rdf:type schema:Person
238 sg:person.0770006522.11 schema:affiliation grid-institutes:grid.9707.9
239 schema:familyName Kawashiri
240 schema:givenName Masa-aki
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770006522.11
242 rdf:type schema:Person
243 sg:pub.10.1007/8904_2014_404 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040856556
244 https://doi.org/10.1007/8904_2014_404
245 rdf:type schema:CreativeWork
246 sg:pub.10.1038/nature13917 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025090131
247 https://doi.org/10.1038/nature13917
248 rdf:type schema:CreativeWork
249 sg:pub.10.1038/ng.2480 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024601187
250 https://doi.org/10.1038/ng.2480
251 rdf:type schema:CreativeWork
252 sg:pub.10.1038/ng.2795 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043368998
253 https://doi.org/10.1038/ng.2795
254 rdf:type schema:CreativeWork
255 grid-institutes:None schema:alternateName Immuno-Biological Laboratories Co., Ltd, Fujioka, Japan
256 schema:name Immuno-Biological Laboratories Co., Ltd, Fujioka, Japan
257 rdf:type schema:Organization
258 grid-institutes:grid.256642.1 schema:alternateName Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan
259 schema:name Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan
260 rdf:type schema:Organization
261 grid-institutes:grid.411998.c schema:alternateName Department of General Medicine, Kanazawa Medical University, Uchinada, Japan
262 schema:name Department of General Medicine, Kanazawa Medical University, Uchinada, Japan
263 rdf:type schema:Organization
264 grid-institutes:grid.9707.9 schema:alternateName Department of Advanced Research in Community Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
265 Department of Laboratory Science, Molecular Biochemistry and Molecular Biology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
266 Division of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, 920-8641, Kanazawa, Japan
267 schema:name Department of Advanced Research in Community Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
268 Department of Laboratory Science, Molecular Biochemistry and Molecular Biology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
269 Division of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, 920-8641, Kanazawa, Japan
270 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...